ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

ClinicalTrials.gov ID: NCT00914589

Public ClinicalTrials.gov record NCT00914589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment With Two Different Doses of Recombinant Factor XIII Following Cardiopulmonary Bypass Surgery

Study identification

NCT ID
NCT00914589
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
479 participants

Conditions and interventions

Interventions

  • catridecacog Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2009
Primary completion
Jan 31, 2011
Completion
Jan 31, 2011
Last update posted
Mar 6, 2017

2009 – 2011

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Novo Nordisk Investigational Site Atlanta Georgia 30322-1059
Novo Nordisk Investigational Site Durham North Carolina 27710
Novo Nordisk Investigational Site Portland Oregon 97239-3098
Novo Nordisk Investigational Site Allentown Pennsylvania 18105
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107
Novo Nordisk Investigational Site Providence Rhode Island 02905
Novo Nordisk Investigational Site Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00914589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2017 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00914589 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →